Profile data is unavailable for this security.
About the company
4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.
- Revenue in GBP (TTM)354.00k
- Net income in GBP-6.28m
- Incorporated2020
- Employees--
- Location4Basebio PLC25 Norman Way, OverCAMBRIDGE CB24 5QEUnited KingdomGBR
- Phone+44 12 2396 7943
- Websitehttps://www.4basebio.com/
Peer analysis
Company | Revenue (TTM) | Net income (TTM) |
---|---|---|
Scancell Holdings Plc | 0.00 | -11.32m |
Futura Medical PLC | 3.10m | -6.51m |
Animalcare Group Plc | 74.35m | 1.20m |
Allergy Therapeutics plc | 53.26m | -50.22m |
Avacta Group Plc | 16.03m | -42.08m |
Faron Pharmaceuticals Oy | 0.00 | -26.49m |
4Basebio PLC | 354.00k | -6.28m |
hVIVO PLC | 56.04m | 16.12m |
Alliance Pharma plc | 170.05m | -7.06m |
Bioventix PLC | 13.60m | 8.67m |
Institutional shareholders
Holder | Shares | % Held |
---|---|---|
Aramea Asset Management AGas of 30 Jun 2022 | 143.33k | 1.12% |
Deutsche Bank AG (Private Banking Germany)as of 30 Apr 2024 | 51.67k | 0.40% |
DWS Investment GmbHas of 31 Jan 2024 | 23.36k | 0.18% |